Neurodevelopmental disorder therapy
AssigneeAnavex Life Sciences Corp.
InventorChristopher U. Missling
Life of this patent
Estimating the term…
Abstract
This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
Claims20
A method of treating Rett syndrome in a subject by administering to said subject a composition comprising a therapeutically effective amount of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (A2-73);
- wherein the therapeutically effective amount is a dosage from about 0.5 mg/day to about 100 mg/day;
- and wherein the composition is selected from an oral composition, a transdermal composition, a parenteral composition, and an intravenous composition.
Dependencies are inferred from the claim text.